Jan 20, 2023 20:31 JST
Source: EC Healthcare
|
|
EC Healthcare Expects Third Quarter FY23 Sales Volume to Increase no less than 8% YoY
- Medical Services Sales Volume to Increase no less than 39% YoY - Business Momentum Building Amid Initial Phase of Border Re-opening
HONG KONG, Jan 20, 2023 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group expects sales volume for the period of October to December 2022 (the "Quarter") to increase by no less than 8% as compared with the same period last year.
The demand on medical services provided by the Group remains strong and the Group's increasingly diversified business demonstrated resilience and good momentum. The Board expects to record overall sales volume of no less than HK$1,000 million for the Quarter, representing a no less than 8% YoY increase. The Group expects to achieve a no less than 39% YoY increase for medical services sales volume. Sales volume of aesthetic medical and beauty and wellness services in Hong Kong and Macau declined by no more than 17% YoY, while sales volume of aesthetic medical and beauty and wellness services in Mainland China declined by no more than 50% YoY during the Quarter. The decrease in aesthetic medical and beauty and wellness services was mainly due to (i) weaker local consumer spending due to increase in outbound traveling amid the lifting of inbound quarantine restrictions; (ii) the pessimistic economic outlook and weak local consumer sentiment caused by high inflation and rising interest rate; and (iii) the omicron outbreak in Mainland China. In addition, the sales volume of other services declined by no less than 8% YoY.
Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The Group is pleased to see the initial phase of border re-opening between Hong Kong and Mainland implemented earlier this year and the Mainland visitors started to return on a gradual basis. With the leading brand and one-stop diversified services, the Group has always been the top choice for medical tourists. The Group has maintained its leading position in the aesthetic medical industry while significantly strengthening its medical services capabilities. In addition, the Group's continuous investment in IT systems and industry value chain integration has enabled the Group to seize the growth opportunity and capture demand from medical tourists. The Group will provide quality, affordable, accessible and sustainable healthcare services to a wider range of customers and continue to expand its businesses through organic growth as well as mergers and acquisitions to enrich the Group's enclosed diversified ecosystem. The Group will also further enhance the resilience and ability to resist cyclical economic changes and further consolidate the healthcare market."
About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.
The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.
*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021
For further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Tim Tin Tel: (852) 2136 6952 / 2169 0467 / 3920 7654 Fax: (852) 3170 6606 Email: ech@iprogilvy.com
Sectors: Healthcare & Pharm
Copyright ©2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Honda: Production, Sales and Export Results for December, 2022 Jan 31, 2023 11:57 JST
|  Mazda Production and Sales Results for December 2022 and for January through December 2022 Jan 31, 2023 11:08 JST
|  DOCOMO Conducts World's First Trial of Transmissive Metasurface on Window to Deliver Indoor Radio Waves to Outdoor Foot of Building Jan 30, 2023 17:00 JST
|  Small, Efficient 5G Multisector Antenna Indoor Base Station Achieves World's First Demonstration using 28GHz Jan 30, 2023 16:35 JST
|  DOCOMO and YKK AP to Test Signal-permeable Windows Made with Aerogel for Easy Penetration by Radio Waves Jan 30, 2023 16:13 JST
|  NEC announces plans for transition to a Company with a Nominating Committee, etc. and implementation of organizational reforms Jan 30, 2023 15:44 JST
|  NEC announces executive personnel changes Jan 30, 2023 15:28 JST
|  Toyota: Sales, Production, and Export Results for 2022 (January - December) Jan 30, 2023 13:36 JST
|  Lecanemab Receives Priority Review Status in Japan Jan 30, 2023 12:50 JST
|  Two Hitachi Group Companies to Merge to Expand Robotic SI Business in Japan and ASEAN Countries Jan 30, 2023 11:08 JST
|  Toyota Tsusho, IIJ, NEC, and NTT Com Sign Contract with Uzbektelecom for Telecommunications Infrastructure Development Project Jan 27, 2023 15:25 JST
|  Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency Jan 27, 2023 11:46 JST
|  TMC Announces Changes to Executive Structure Jan 27, 2023 10:59 JST
|  Nippon Steel, Mitsubishi Corporation and ExxonMobil to Evaluate and Establish CCS Value Chains in the Asia Pacific Region Jan 26, 2023 19:16 JST
|  Kurita Water Industries and Hitachi Launch a Co-creation to Implement Solution in Society and Build an Ecosystem for a Sustainable Society with "Zero Environmental Impact" Jan 26, 2023 19:02 JST
|  Four Companies Announce Joint Feasibility Study of Large-Scale and Wide-Area Carbon Capture and Storage (CCS) Value Chain Project Using Ship Transportation Jan 26, 2023 18:28 JST
|  Mitsubishi Power Receives Order for H-25 Gas Turbine for Taiwan's Chang Chun Petrochemical Jan 26, 2023 18:22 JST
|  Fujitsu and Mizuho Bank embark on collaboration for sustainable management information services Jan 26, 2023 13:44 JST
|  All-New eK X EV Earns Top Rating in Vehicle Safety Performance 2022 Car Assessment by JNCAP Jan 26, 2023 09:01 JST
|  DOCOMO Announces World's First Technology that Utilizes Human-Augmentation Platform for Sharing Haptic Information Between People Jan 25, 2023 17:17 JST
|
More Latest Release >>
|